C-AM-01
Prevention of Severe Migraine with Aura
Phase 2Active
Key Facts
About Curatis Pharma
Curatis Pharma is a private, Switzerland-based biopharmaceutical company with a dual-strategy approach. Its core business involves the exclusive distribution of over 40 third-party orphan and specialty medicines in Switzerland, providing a commercial foundation. Concurrently, it is developing a pipeline of four internal drug candidates, primarily in Phase II, targeting conditions like peritumoral brain edema and severe migraine. The company's strategy leverages existing clinical data for lower-risk development and seeks growth through geographic expansion and eventual public listing.
View full company profile